TOX

Gene

Also known as: TOX

Related News

Biomarkers and T Cell Traits Emerge as Key Predictors of Cancer Immunotherapy Response

Feb 17, 2026

New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.

TET2 Mutations Enhance Cancer Immunotherapy Response in New Studies

Feb 14, 2026

Research shows TET2-driven clonal hematopoiesis improves immune checkpoint blockade efficacy in solid tumors, while separate studies identify new immune pathways in childhood brain cancers and mechanisms behind immunotherapy resistance.